Tarsus Pharmaceuticals, Inc. Annual Income Tax Expense (Benefit) in USD from 2019 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Tarsus Pharmaceuticals, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2019 to 2024.
  • Tarsus Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2023 was $0.000.
  • Tarsus Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2023 was $0.000.
  • Tarsus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was $0.000.
  • Tarsus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000.
  • Tarsus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$4K, a 107% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $0 $0 Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 $0 +$4K Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 -$4K -$59K -107% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-25
2021 $55K +$54K +5400% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-17
2020 $1K $0 0% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-14
2019 $1K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.